Cerenome, Inc.

Healthcare · Medical - Pharmaceuticals · United States

Last price 1.74 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 13.21M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary li...